Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.

The process of discovering new drugs is both challenging and inefficient. A contributing factor is the inability of traditional preclinical experiments to predict drug safety and efficacy in humans. To bridge the gap between traditional preclinical models and human studies, Organ-on-a-chip (OOC) advances towards the simulation of human biological conditions in the lab. The technology provides predictive, human-relevant data to facilitate more informed decisions about which medicines to take into the clinic. Its potential has piqued regulator interest and, alongside other new approach methodologies (NAMS), is driving regulatory change.

In this webinar, CN Bio’s PhysioMimix OOC Product Manager, Dr. Audrey Dubourg, and Lead Scientist Dr. Gareth Guenigault explore the value that an OOC approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.

Using Liver-on-a-chip as an example, the webinar will explore how OOC technology supports researchers to uncover novel mechanistic insights into a broad range of biological processes, identify novel therapeutic targets, investigate drug efficacy, profile pharmacokinetics and flag potential toxicity. Case study data from pharma/biotech and our long-standing collaboration with the US FDA will be presented to demonstrate how predictive OOC data is improving the efficiency of drug discovery.

Key Topics Include:

  • What’s Organ-on-a-Chip (OOC) & how does it address the current limitations of preclinical drug discovery?
  • The current regulatory landscape
  • Liver-on-a-chip models & key applications: modeling disease, predicting drug metabolism, bioavailability, and toxicity
  • How to use OOC to generate robust and reliable data that translates into clinical outcomes
  • Key case study data with Pharma, Biotech, and the US FDA
  • Accessing CN Bio’s PhysioMimix™ OOC range of products and services

Presenters

Lead Scientist
CN Bio

Dr. Gareth Guenigault is a Lead Scientist at CN Bio, an Organ-on-a-Chip company based in Cambridge UK. Gareth is responsible for the Contract Research Services arm of CN Bio’s business, where he oversees the design and implementation of customer studies to test novel therapeutic candidates using the company's advanced in vitro 3D models. Gareth and his team have played an instrumental role in the development of CN Bio’s human NASH model. They have created a set of highly customizable, industry-proven, set of assays that replicate the key elements of human non-alcoholic fatty liver disease and NASH. Before joining CN Bio, Gareth completed a PhD at Cardiff University before accepting a Post-Doc position at Cambridge University focused on the fields of Virology and Immunology.

Product Manager
CN Bio

Dr. Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix™ OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.

Production Partner

CN Bio

CN Bio is a close-knit team of passionate scientists, engineers, and creative thinkers, all working together towards a shared goal – a future where drugs are discovered more quickly, brought to patients more cost-effectively, and through the use of less animal experimentation. Day to day our cohesive team designs, manufactures, promotes, and supports organ-on-a-chip solutions that enable our customers to do something incredible – recreate three-dimensional human organs and tissues in the laboratory to better understand human physiology, disease, and the effectiveness of new drugs.

Additional Content From Scientist.com

Related Content

Rethink your Impurity Analysis Strategy

Rethink your Impurity Analysis Strategy

In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.